APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Liraglutide for The Treatment of Diabetes and Obesity

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Liraglutide for The Treatment of Diabetes and Obesity Market Outlook and Growth Opportunities 2026

27 December 2025193 pages

Choose your research edition.

Industry ResearchLiraglutide for The Treatment of Diabetes and Obesity Industry Research Report 2026110 pages · $2,950 USDIndustry Growth & TrendsGlobal Liraglutide for The Treatment of Diabetes and Obesity Industry Growth and Trends Forecast to 203271 pages · $3,450 USDMarket StructureGlobal Liraglutide for The Treatment of Diabetes and Obesity Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032172 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Liraglutide for The Treatment of Diabetes and Obesity Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Liraglutide for The Treatment of Diabetes and Obesity Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Liraglutide for The Treatment of Diabetes and Obesity market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Liraglutide for The Treatment of Diabetes and Obesity is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Liraglutide for The Treatment of Diabetes and Obesity is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Liraglutide for The Treatment of Diabetes and Obesity is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Liraglutide for The Treatment of Diabetes and Obesity market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Liraglutide for The Treatment of Diabetes and Obesity market include Huadong Medicine, Sino Biopharm, Teva and Novo Nordisk, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Liraglutide for The Treatment of Diabetes and Obesity market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Liraglutide for The Treatment of Diabetes and Obesity and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Liraglutide for The Treatment of Diabetes and Obesity sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Liraglutide for The Treatment of Diabetes and Obesity market size, projected growth trends, production technologies, key applications, and end-use industries.

Liraglutide for The Treatment of Diabetes and Obesity Segment by Company

Huadong Medicine

Sino Biopharm

Teva

Novo Nordisk

Liraglutide for The Treatment of Diabetes and Obesity Segment by Type

Generic Drug

Original Drug

Liraglutide for The Treatment of Diabetes and Obesity Segment by Application

Hospital and Clinic

Retail Pharmacies

Other

Liraglutide for The Treatment of Diabetes and Obesity Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Liraglutide for The Treatment of Diabetes and Obesity status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Liraglutide for The Treatment of Diabetes and Obesity market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Liraglutide for The Treatment of Diabetes and Obesity significant trends, drivers, influence factors in global and regions.

6. To analyze Liraglutide for The Treatment of Diabetes and Obesity competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liraglutide for The Treatment of Diabetes and Obesity market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Liraglutide for The Treatment of Diabetes and Obesity and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liraglutide for The Treatment of Diabetes and Obesity.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Liraglutide for The Treatment of Diabetes and Obesity market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Liraglutide for The Treatment of Diabetes and Obesity industry.

Chapter 3: Detailed analysis of Liraglutide for The Treatment of Diabetes and Obesity manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Liraglutide for The Treatment of Diabetes and Obesity in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Liraglutide for The Treatment of Diabetes and Obesity in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Liraglutide for The Treatment of Diabetes and Obesity Industry Trends Table 2. Liraglutide for The Treatment of Diabetes and Obesity Industry Drivers Table 3. Liraglutide for The Treatment of Diabetes and Obesity Industry Opportunities and Challenges Table 4. Liraglutide for The Treatment of Diabetes and Obesity Industry Restraints Table 5. Global Liraglutide for The Treatment of Diabetes and Obesity Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Liraglutide for The Treatment of Diabetes and Obesity Revenue Share by Company (2021-2026) Table 7. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Volume Share by Company (2021-2026) Table 9. Global Liraglutide for The Treatment of Diabetes and Obesity Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Liraglutide for The Treatment of Diabetes and Obesity Company Ranking, (2024-2026) & (USD Million) Table 11. Global Liraglutide for The Treatment of Diabetes and Obesity Key Company Manufacturing Base & Headquarters Table 12. Global Liraglutide for The Treatment of Diabetes and Obesity Company, Product Type & Application Table 13. Global Liraglutide for The Treatment of Diabetes and Obesity Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Liraglutide for The Treatment of Diabetes and Obesity by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Generic Drug Table 18. Significant Companies of Original Drug Table 19. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Volume Share by Type (2021-2026) Table 23. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Volume Share by Type (2027-2032) Table 24. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type (2021-2026) Table 28. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital and Clinic Table 30. Significant Companies of Retail Pharmacies Table 31. Significant Companies of Other Table 32. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Volume Share by Application (2021-2026) Table 36. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Volume Share by Application (2027-2032) Table 37. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application (2021-2026) Table 41. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application (2027-2032) Table 42. Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Region (2021-2026) & (K Units) Table 44. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Region (2021-2026) Table 45. Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Region (2027-2032) & (K Units) Table 46. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Region (2027-2032) Table 47. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Region (2021-2026) Table 50. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Region (2027-2032) Table 52. Global Liraglutide for The Treatment of Diabetes and Obesity Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Liraglutide for The Treatment of Diabetes and Obesity Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (2021-2026) & (K Units) Table 57. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Country (2021-2026) Table 58. Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (2027-2032) & (K Units) Table 59. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Country (2027-2032) Table 60. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value Market Share by Country (2021-2026) Table 62. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value Market Share by Country (2027-2032) Table 64. Huadong Medicine Company Information Table 65. Huadong Medicine Business Overview Table 66. Huadong Medicine Liraglutide for The Treatment of Diabetes and Obesity Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Huadong Medicine Liraglutide for The Treatment of Diabetes and Obesity Product Portfolio Table 68. Huadong Medicine Recent Development Table 69. Sino Biopharm Company Information Table 70. Sino Biopharm Business Overview Table 71. Sino Biopharm Liraglutide for The Treatment of Diabetes and Obesity Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Sino Biopharm Liraglutide for The Treatment of Diabetes and Obesity Product Portfolio Table 73. Sino Biopharm Recent Development Table 74. Teva Company Information Table 75. Teva Business Overview Table 76. Teva Liraglutide for The Treatment of Diabetes and Obesity Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Teva Liraglutide for The Treatment of Diabetes and Obesity Product Portfolio Table 78. Teva Recent Development Table 79. Novo Nordisk Company Information Table 80. Novo Nordisk Business Overview Table 81. Novo Nordisk Liraglutide for The Treatment of Diabetes and Obesity Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Novo Nordisk Liraglutide for The Treatment of Diabetes and Obesity Product Portfolio Table 83. Novo Nordisk Recent Development Table 84. Key Raw Materials Table 85. Raw Materials Key Suppliers Table 86. Liraglutide for The Treatment of Diabetes and Obesity Distributors List Table 87. Liraglutide for The Treatment of Diabetes and Obesity Customers List Table 88. Research Programs/Design for This Report Table 89. Authors List of This Report Table 90. Secondary Sources Table 91. Primary Sources List of Figures Figure 1. Liraglutide for The Treatment of Diabetes and Obesity Product Image Figure 2. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value (2021-2032) & (US$ Million) Figure 4. Global Liraglutide for The Treatment of Diabetes and Obesity Sales (2021-2032) & (K Units) Figure 5. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Liraglutide for The Treatment of Diabetes and Obesity Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Generic Drug Image Figure 10. Original Drug Image Figure 11. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Volume Share by Type (2021-2032) Figure 14. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type (2021-2032) Figure 17. Hospital and Clinic Image Figure 18. Retail Pharmacies Image Figure 19. Other Image Figure 20. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Volume Share by Application (2021-2032) Figure 23. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application (2021-2032) Figure 26. Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Liraglutide for The Treatment of Diabetes and Obesity Sales Value (2021-2032) & (US$ Million) Figure 31. North America Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Liraglutide for The Treatment of Diabetes and Obesity Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Liraglutide for The Treatment of Diabetes and Obesity Sales Value (2021-2032) & (US$ Million) Figure 37. South America Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Liraglutide for The Treatment of Diabetes and Obesity Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Liraglutide for The Treatment of Diabetes and Obesity Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Liraglutide for The Treatment of Diabetes and Obesity Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Generic Drug
  • Original Drug
Applications
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Companies covered
  • Huadong Medicine
  • Sino Biopharm
  • Teva
  • Novo Nordisk

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value (2021-2032)
  4. 1.2.2 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Volume (2021-2032)
  5. 1.2.3 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Liraglutide for The Treatment of Diabetes and Obesity Market Dynamics
  1. 2.1 Liraglutide for The Treatment of Diabetes and Obesity Industry Trends
  2. 2.2 Liraglutide for The Treatment of Diabetes and Obesity Industry Drivers
  3. 2.3 Liraglutide for The Treatment of Diabetes and Obesity Industry Opportunities and Challenges
  4. 2.4 Liraglutide for The Treatment of Diabetes and Obesity Industry Restraints
3 Liraglutide for The Treatment of Diabetes and Obesity Market by Company
  1. 3.1 Global Liraglutide for The Treatment of Diabetes and Obesity Company Revenue Ranking in 2025
  2. 3.2 Global Liraglutide for The Treatment of Diabetes and Obesity Revenue by Company (2021-2026)
  3. 3.3 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Volume by Company (2021-2026)
  4. 3.4 Global Liraglutide for The Treatment of Diabetes and Obesity Average Price by Company (2021-2026)
  5. 3.5 Global Liraglutide for The Treatment of Diabetes and Obesity Company Ranking (2024-2026)
  6. 3.6 Global Liraglutide for The Treatment of Diabetes and Obesity Company Manufacturing Base and Headquarters
  7. 3.7 Global Liraglutide for The Treatment of Diabetes and Obesity Company Product Type and Application
  8. 3.8 Global Liraglutide for The Treatment of Diabetes and Obesity Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Liraglutide for The Treatment of Diabetes and Obesity Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Liraglutide for The Treatment of Diabetes and Obesity Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Liraglutide for The Treatment of Diabetes and Obesity Market by Type
  1. 4.1 Liraglutide for The Treatment of Diabetes and Obesity Type Introduction
  2. 4.1.1 Generic Drug
  3. 4.1.2 Original Drug
  4. 4.2 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Volume by Type
  5. 4.2.1 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value by Type
  9. 4.3.1 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value by Type (2021-2032)
  11. 4.3.3 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type (2021-2032)
5 Liraglutide for The Treatment of Diabetes and Obesity Market by Application
  1. 5.1 Liraglutide for The Treatment of Diabetes and Obesity Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Retail Pharmacies
  4. 5.1.3 Other
  5. 5.2 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Volume by Application
  6. 5.2.1 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value by Application
  10. 5.3.1 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value by Application (2021-2032)
  12. 5.3.3 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application (2021-2032)
6 Liraglutide for The Treatment of Diabetes and Obesity Regional Sales and Value Analysis
  1. 6.1 Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Region (2021-2032)
  3. 6.2.1 Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Region: 2021-2026
  4. 6.2.2 Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Region (2027-2032)
  5. 6.3 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value by Region (2021-2032)
  7. 6.4.1 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value by Region: 2021-2026
  8. 6.4.2 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value by Region (2027-2032)
  9. 6.5 Global Liraglutide for The Treatment of Diabetes and Obesity Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Liraglutide for The Treatment of Diabetes and Obesity Sales Value (2021-2032)
  12. 6.6.2 North America Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Liraglutide for The Treatment of Diabetes and Obesity Sales Value (2021-2032)
  15. 6.7.2 Europe Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Liraglutide for The Treatment of Diabetes and Obesity Sales Value (2021-2032)
  21. 6.9.2 South America Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Liraglutide for The Treatment of Diabetes and Obesity Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Country, 2025 VS 2032
7 Liraglutide for The Treatment of Diabetes and Obesity Country-level Sales and Value Analysis
  1. 7.1 Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (2021-2032)
  4. 7.3.1 Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (2021-2026)
  5. 7.3.2 Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (2027-2032)
  6. 7.4 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value by Country (2021-2032)
  7. 7.4.1 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value by Country (2021-2026)
  8. 7.4.2 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Liraglutide for The Treatment of Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Liraglutide for The Treatment of Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Huadong Medicine
  2. 8.1.1 Huadong Medicine Company Information
  3. 8.1.2 Huadong Medicine Business Overview
  4. 8.1.3 Huadong Medicine Liraglutide for The Treatment of Diabetes and Obesity Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Huadong Medicine Liraglutide for The Treatment of Diabetes and Obesity Product Portfolio
  6. 8.1.5 Huadong Medicine Recent Developments
  7. 8.2 Sino Biopharm
  8. 8.2.1 Sino Biopharm Company Information
  9. 8.2.2 Sino Biopharm Business Overview
  10. 8.2.3 Sino Biopharm Liraglutide for The Treatment of Diabetes and Obesity Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sino Biopharm Liraglutide for The Treatment of Diabetes and Obesity Product Portfolio
  12. 8.2.5 Sino Biopharm Recent Developments
  13. 8.3 Teva
  14. 8.3.1 Teva Company Information
  15. 8.3.2 Teva Business Overview
  16. 8.3.3 Teva Liraglutide for The Treatment of Diabetes and Obesity Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Teva Liraglutide for The Treatment of Diabetes and Obesity Product Portfolio
  18. 8.3.5 Teva Recent Developments
  19. 8.4 Novo Nordisk
  20. 8.4.1 Novo Nordisk Company Information
  21. 8.4.2 Novo Nordisk Business Overview
  22. 8.4.3 Novo Nordisk Liraglutide for The Treatment of Diabetes and Obesity Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Novo Nordisk Liraglutide for The Treatment of Diabetes and Obesity Product Portfolio
  24. 8.4.5 Novo Nordisk Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Liraglutide for The Treatment of Diabetes and Obesity Value Chain Analysis
  2. 9.1.1 Liraglutide for The Treatment of Diabetes and Obesity Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Liraglutide for The Treatment of Diabetes and Obesity Sales Mode & Process
  6. 9.2 Liraglutide for The Treatment of Diabetes and Obesity Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Liraglutide for The Treatment of Diabetes and Obesity Distributors
  9. 9.2.3 Liraglutide for The Treatment of Diabetes and Obesity Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst